Investornewsbreaks Nanoviricides (NYSE American: NNVC) To Present Broad-Spectrum Antiviral Innovations At Biotech Showcase 2025

(MENAFN- Investor Brand Network) NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage company developing antiviral drugs designed to resist viral escape, announced it will present at the Biotech ShowcaseTM 2025 on Jan. 14 in San Francisco. Anil R. Diwan, PhD, the company's president and executive chairman, will provide updates on NanoViricides' pipeline, including NV-387, a Phase II-ready drug with potential applications against a wide range of viral infections such as influenza, RSV, MPox, smallpox, and COVID-19. NV-387 is engineered to target host-side features essential for viral infections, offering potential advantages over current treatments. The company will also showcase its platform for oral delivery of non-oral drugs, which could meet significant market demand. The market potential for NV-387's indications exceeds $10 billion. Biotech Showcase runs parallel to the JP Morgan Life Sciences Conference, offering a key networking venue for therapeutic development executives and investors.

To view the full press release, visit

About NanoViricides Inc.

NanoViricides is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. The company's novel nanoviricide(TM) class of drug candidates and the nanoviricide(TM) technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. NanoViricides' lead drug candidate is NV-387, a broad-spectrum antiviral drug that the company plans to develop as a treatment of RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is currently focused on advancing NV-387 into Phase II human clinical trials. NanoViricides' other advanced candidate is NV-HHV-1 for the treatment of Shingles. The company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants.
NV-CoV-2 (“API NV-387”) is the company's nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is NanoViricides' other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. For more information about the company, visit
.

NOTE TO INVESTORS:
The latest news and updates relating to NNVC are available in the company's newsroom at

About InvestorWire

InvestorWire
(“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:
/Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by
IBN

MENAFN13012025000224011066ID1109085558